ArticleEuropean heart journal open2021

Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation.

Paul C Cremer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.